FGAM
AXSM icon

Financial Gravity Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Financial Gravity Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$87 – 1439
2024
Q1 		$87 Buy
+1
New +$84 ﹤0.01% 977
2023
Q4 		– Hold
0
– – – 1111
2021
Q3 		$33K Hold
1
– – 0.02% 682
2021
Q2 		$67K Buy
+1
New +$60 0.02% 472

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Financial Gravity Asset Management's AXSM Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Axsome Therapeutics (AXSM) in Q2 2024, closing a stake of 1 share — an estimated $87 sold.

Financial Gravity Asset Management first reported a position in AXSM in Q2 2021 and held it in 3 quarters. The position peaked at $67K in Q2 2021. 256 funds tracked by Wall St. Rank hold AXSM as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Axsome Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 1 Axsome Therapeutics share in Q2 2024, an estimated $87.
  • Financial Gravity Asset Management first reported a position in Axsome Therapeutics in Q2 2021 and held it in 3 quarters.
  • Financial Gravity Asset Management's Axsome Therapeutics position peaked at $67K in Q2 2021.
  • 256 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.